Canada - English - Health Canada

omega laboratories limited - allergenic extract non-pollen - liquid - 40000unit - allergenic extract non-pollen 40000unit - allergenic extracts

Canada - English - Health Canada

omega laboratories limited - allergenic extract non-pollen - liquid - 40000unit - allergenic extract non-pollen 40000unit - allergenic extracts

Canada - English - Health Canada

greer laboratories inc - pollen - liquid - 40000unit - pollen 40000unit - allergenic extracts

United States - English - NLM (National Library of Medicine)

jubilant hollisterstier llc - sorghum halepense pollen (unii: 577va5b4hp) (sorghum halepense pollen - unii:577va5b4hp) - sorghum halepense pollen 0.1 g in 1 ml - allergenic extracts are indicated for use in diagnosis and immunotherapy of patients presenting symptoms of allergy (hay fever, rhinitis, etc.) to specific environmental allergens. the selection of allergenic extracts to be used should be based on a thorough and carefully taken history of hypersensitivity, and confirmed by skin testing. the use of mixed or unrelated antigens for skin testing is not recommended since, in the case of a positive reaction, it does not indicate which component of the mix is responsible for the reaction, while, in the case of a negative reaction, it fails to indicate whether the individual antigens at full concentration would give a positive reaction. utilization of such mixes for compounding a treatment may result, in the former case, in administering unnecessary antigens and, in the latter case, in the omission of a needed antigen. avoidance of allergens is to be advocated if possible, but cannot always be attained, e.g., allergy to dog dander in kennel owners and employees,

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - cynodon dactylon pollen (unii: 175f461w10) (cynodon dactylon pollen - unii:175f461w10) - cynodon dactylon pollen 10000 [bau] in 1 ml - indicated use of allergenic extracts is for the diagnosis and treatment (hyposensitization therapy) of patients who experience allergic symptoms due to exposure to grass pollen and who exhibit type i skin sensitivity when tested to those specific allergens. hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust mites, molds, animal danders, and various other inhalants in situations where the offending allergen cannot be avoided. for previously untreated patients, prior to the initiation of therapy, clinical sensitivity to the standardized grass pollen extract should be established by careful evaluation of the patient's history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. 10,000 bau/ml extracts are indicated for percutaneous testing. if negative, the 100,000 bau/ml dose may be used. availability of 10,000 and 100,000 bau/ml dosages facilitate safe

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - solidago canadensis pollen (unii: 644cz16ir5) (solidago canadensis pollen - unii:644cz16ir5) - equus caballus skin 20000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - olea europaea, quantity: 10 ir/ml - injection, suspension - excipient ingredients: sodium chloride; phenol; mannitol; aluminium hydroxide hydrate; water for injections - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - olea europaea, quantity: 10 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; sodium chloride; mannitol; phenol; water for injections - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

United States - English - NLM (National Library of Medicine)

jubilant hollisterstier llc - bassia scoparia pollen (unii: 07a108zkw5) (bassia scoparia pollen - unii:07a108zkw5) - bassia scoparia pollen 0.05 g in 1 ml - allergenic extracts are indicated for use in diagnosis and immunotherapy of patients presenting symptoms of allergy (hay fever, rhinitis, etc.) to specific environmental allergens. the selection of allergenic extracts to be used should be based on a thorough and carefully taken history of hypersensitivity, and confirmed by skin testing. the use of mixed or unrelated antigens for skin testing is not recommended since, in the case of a positive reaction, it does not indicate which component of the mix is responsible for the reaction, while, in the case of a negative reaction, it fails to indicate whether the individual antigens at full concentration would give a positive reaction. utilization of such mixes for compounding a treatment may result, in the former case, in administering unnecessary antigens and, in the latter case, in the omission of a needed antigen. avoidance of allergens is to be advocated if possible, but cannot always be attained, e.g., allergy to dog dander in kennel owners and employees,

United States - English - NLM (National Library of Medicine)

jubilant hollisterstier llc - artemisia vulgaris pollen (unii: ant994t71d) (artemisia vulgaris pollen - unii:ant994t71d) - artemisia vulgaris pollen 0.05 g in 1 ml - allergenic extracts are indicated for use in diagnosis and immunotherapy of patients presenting symptoms of allergy (hay fever, rhinitis, etc.) to specific environmental allergens. the selection of allergenic extracts to be used should be based on a thorough and carefully taken history of hypersensitivity, and confirmed by skin testing. the use of mixed or unrelated antigens for skin testing is not recommended since, in the case of a positive reaction, it does not indicate which component of the mix is responsible for the reaction, while, in the case of a negative reaction, it fails to indicate whether the individual antigens at full concentration would give a positive reaction. utilization of such mixes for compounding a treatment may result, in the former case, in administering unnecessary antigens and, in the latter case, in the omission of a needed antigen. avoidance of allergens is to be advocated if possible, but cannot always be attained, e.g., allergy to dog dander in kennel owners and employees,